Importance of higher infliximab trough level maintenance compared with the HLA-DQA1*05 polymorphism in preventing anti-infliximab antibodies and loss of response to infliximab
Inflammatory Bowel Diseases · 01.11.2026 · 32 (11) · 2232-2236
DOI: 10.1093/ibd/izag108 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 23.06.2026. Verfasst von Joana Revés und 6 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Division, Hospital Beatriz Ângelo, Loures, 2674-514, Portugal. Hauptthemen laut MEDLINE: Infliximab, HLA-DQ alpha-Chains, Polymorphism, Genetic, Inflammatory Bowel Diseases. Die Arbeit nennt 12 Literaturangaben. Gefördert von: Third Place in Health Research Prize, supported by Merck Sharp & Dohme, Fundação para a Ciência e a Tecnologia, Research Unit on Applied Molecular Biosciences.
Abstract (Originalsprache)
In this single-center cohort of patients with inflammatory bowel disease (IBD) managed with proactive infliximab monitoring, HLA-DQA1*05 was not associated with immunogenicity or loss of response, whereas higher infliximab (IFX) drug levels and concomitant immunomodulator therapy independently reduced the risk of both outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology Division, Hospital Beatriz Ângelo, Loures, 2674-514, Portugal.
- Gastroenterology Division, Hospital da Luz, Lisbon, 1500-650, Portugal.
- Investigation Centre, Hospital da Luz Learning Health, Lisbon, 1500-650, Portugal.
- Associate Laboratory i4HB-Institute for Health and Bioeconomy, NOVA School of Science and Technology, NOVA University Lisbon, Caparica, 2819-516, Portugal.
- UCIBIO-Applied Molecular Biosciences Unit, Department of Life Sciences, NOVA School of Science and Technology, NOVA University Lisbon, Caparica, 2819-516, Portugal.
- Faculty of Medicine, University of Lisbon, Lisbon, 1649-028, Portugal.
ORCID-Profile: Joana Revés, Joana Torres
Förderung
- Third Place in Health Research Prize, supported by Merck Sharp & Dohme
- Fundação para a Ciência e a Tecnologia
- Research Unit on Applied Molecular Biosciences
- Associate Laboratory Institute for Health and Bioeconomy
- Third Place in Health Research Prize
Zitieren
APA
Revés, J., Guedes, A., Bravo, A. C., Sá, M., Baptista, P. V., Fernandes, A. R., & Torres, J. (2026). Importance of higher infliximab trough level maintenance compared with the HLA-DQA1*05 polymorphism in preventing anti-infliximab antibodies and loss of response to infliximab. Inflammatory Bowel Diseases, 32(11), 2232-2236. https://doi.org/10.1093/ibd/izag108
Vancouver
Revés J, Guedes A, Bravo AC, Sá M, Baptista PV, Fernandes AR, et al. Importance of higher infliximab trough level maintenance compared with the HLA-DQA1*05 polymorphism in preventing anti-infliximab antibodies and loss of response to infliximab. Inflammatory Bowel Diseases. 2026;32(11):2232-2236. doi:10.1093/ibd/izag108
BibTeX
@article{Revs2026,
author = {Revés, Joana and Guedes, Ana and Bravo, Ana Catarina and Sá, Maria and Baptista, Pedro Viana and Fernandes, Alexandra Ramos and Torres, Joana},
title = {Importance of higher infliximab trough level maintenance compared with the HLA-DQA1*05 polymorphism in preventing anti-infliximab antibodies and loss of response to infliximab},
journal = {Inflammatory Bowel Diseases},
year = {2026},
volume = {32},
number = {11},
pages = {2232--2236},
doi = {10.1093/ibd/izag108}
}
EUVIMED